These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 20213024)

  • 21. Low glucose degradation product peritoneal dialysis regimen is associated with lower plasma EN-RAGE and HMGB-1 proinflammatory ligands of receptor for advanced glycation end products.
    Opatrna S; Popperlova A; Kalousová M; Zima T
    Ther Apher Dial; 2014 Jun; 18(3):309-16. PubMed ID: 24965297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RAGE and RAGE ligands in cancer.
    Logsdon CD; Fuentes MK; Huang EH; Arumugam T
    Curr Mol Med; 2007 Dec; 7(8):777-89. PubMed ID: 18331236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Perspectives on RAGE signaling and its role in cardiovascular disease.
    Cohen MM
    Am J Med Genet A; 2013 Nov; 161A(11):2750-5. PubMed ID: 24123885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Receptor for Advanced Glycation End Products (RAGE) in Type 1 Diabetes Pathogenesis.
    Leung SS; Forbes JM; Borg DJ
    Curr Diab Rep; 2016 Oct; 16(10):100. PubMed ID: 27612847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RAGE as a receptor of HMGB1 (Amphoterin): roles in health and disease.
    Rauvala H; Rouhiainen A
    Curr Mol Med; 2007 Dec; 7(8):725-34. PubMed ID: 18331230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease.
    Bucciarelli LG; Wendt T; Rong L; Lalla E; Hofmann MA; Goova MT; Taguchi A; Yan SF; Yan SD; Stern DM; Schmidt AM
    Cell Mol Life Sci; 2002 Jul; 59(7):1117-28. PubMed ID: 12222959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Receptors for advanced glycation end products and their physiological and clinical significance].
    Pietkiewicz J; Seweryn E; Bartyś A; Gamian A
    Postepy Hig Med Dosw (Online); 2008 Oct; 62():511-23. PubMed ID: 18936727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting receptors of advanced glycation end products (RAGE): Preventing diabetes induced cancer and diabetic complications.
    Chhipa AS; Borse SP; Baksi R; Lalotra S; Nivsarkar M
    Pathol Res Pract; 2019 Nov; 215(11):152643. PubMed ID: 31564569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The biology of RAGE and its ligands: uncovering mechanisms at the heart of diabetes and its complications.
    Yan SF; Barile GR; D'Agati V; Du Yan S; Ramasamy R; Schmidt AM
    Curr Diab Rep; 2007 Apr; 7(2):146-53. PubMed ID: 17425919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings.
    Stern D; Yan SD; Yan SF; Schmidt AM
    Adv Drug Deliv Rev; 2002 Dec; 54(12):1615-25. PubMed ID: 12453678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of the receptor of advanced glycation end products in the gingival tissue of smokers with generalized periodontal disease and after nornicotine induction in primary gingival epithelial cells.
    Katz J; Yoon TY; Mao S; Lamont RJ; Caudle RM
    J Periodontol; 2007 Apr; 78(4):736-41. PubMed ID: 17397323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Understanding RAGE, the receptor for advanced glycation end products.
    Bierhaus A; Humpert PM; Morcos M; Wendt T; Chavakis T; Arnold B; Stern DM; Nawroth PP
    J Mol Med (Berl); 2005 Nov; 83(11):876-86. PubMed ID: 16133426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RAGE: the beneficial and deleterious effects by diverse mechanisms of actions.
    Han SH; Kim YH; Mook-Jung I
    Mol Cells; 2011 Feb; 31(2):91-7. PubMed ID: 21347704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease.
    Sasaki N; Toki S; Chowei H; Saito T; Nakano N; Hayashi Y; Takeuchi M; Makita Z
    Brain Res; 2001 Jan; 888(2):256-262. PubMed ID: 11150482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RAGE-mediated cell signaling.
    Rouhiainen A; Kuja-Panula J; Tumova S; Rauvala H
    Methods Mol Biol; 2013; 963():239-63. PubMed ID: 23296615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Upregulation of RAGE and its ligands in proliferative retinal disease.
    Pachydaki SI; Tari SR; Lee SE; Ma W; Tseng JJ; Sosunov AA; Cataldergirmen G; Scarmeas N; Caspersen C; Chang S; Schiff WM; Schmidt AM; Barile GR
    Exp Eye Res; 2006 May; 82(5):807-15. PubMed ID: 16364297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response.
    Clynes R; Moser B; Yan SF; Ramasamy R; Herold K; Schmidt AM
    Curr Mol Med; 2007 Dec; 7(8):743-51. PubMed ID: 18331232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications.
    Yan SF; Ramasamy R; Schmidt AM
    Nat Clin Pract Endocrinol Metab; 2008 May; 4(5):285-93. PubMed ID: 18332897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics.
    Valencia JV; Weldon SC; Quinn D; Kiers GH; DeGroot J; TeKoppele JM; Hughes TE
    Anal Biochem; 2004 Jan; 324(1):68-78. PubMed ID: 14654047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease.
    Yan SF; Ramasamy R; Schmidt AM
    Expert Rev Mol Med; 2009 Mar; 11():e9. PubMed ID: 19278572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.